Business
Trevi Therapeutics to Participate in Upcoming May Investor Events
2023 Aegis Virtual Conference, May 2-4 American Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20 Yale Innovation Summit, May
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"2023 Aegis Virtual Conference, May 2-4\nAmerican Thoracic Society's (ATS) 2023 Respiratory Innovation Summit (RIS), May 19-20\nYale Innovation Summit, May 31-June 1\nNEW HAVEN, Conn., April 27, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced senior management will attend and present at the following May 2023 investor events.\n\n \n \n \n \n \n \n\n \n2023 Aegis Virtual Conference (May 2-4)Presenters: Jennifer Good, President and CEO, and Lisa Delfini, CFOPresentation: Wednesday, May 3rd, 4:30-5:00 PM ET\nAmerican Thoracic Society's 2023 Respiratory Innovation Summit (RIS) (May 19-20)Presenter: Jennifer Good, President and CEOPresentation: Saturday, May 20, 10:35-10:40 AM ETShowcase: Showcase Two: Critical Care, Chronic Cough and Sleep InnovatorsRegistration: Investors and analysts can register to attend the in-person event by using the following link: https://conference.thoracic.org/program/ris/\nYale Innovation Summit (May 31-June 1)Presenters: Jennifer Good, President and CEO of Trevi Therapeutics, Farrell Simon, Chief Commercial Officer of Trevi Therapeutics, and Peter Dicpinigaitis, MD, Professor of Medicine, Albert Einstein College of Medicine, Division of Critical Care Medicine, Montefiore Medical Center, Director, Montefiore Cough Center and Editor-in-Chief, LUNGPresentation: Thursday, June 1, 10:30 AM-12 PM ETRegistration: Investors and analysts can register to attend the in-person event by using the following link: https://ventures.yale.edu/yale-innovation-summit\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing Haduvio, an investigational therapy in an oral extended-release formulation of nalbuphine, for the treatment of chronic cough in IPF and other chronic cough indications. Haduvio is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally and peripherally. The ĸ and µ receptors are known critical mediators of cough. Parenteral nalbuphine has been approved and marketed for over 20 years for the treatment of acute ...